First-in-human Phase i study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer.
British Journal of Cancer.
Times cited: 37
A phase I study of sequential vinorelbine followed by paclitaxel.
Annals of Oncology.
Times cited: 12